demonstrated that miR-155 was aberrantly upregulated in a STAT5-dependent manner for individuals with a greater level of class IV GCSFR, suggesting that upregulated miR-155 can increase the risk of de novo leukemia or leukemia relapse for these individuals. This evidence concerns the gene STAT5A and leukemia.